# A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

> **NCT06275620** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Beacon Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** AGTC-501 (high dose and standard corticosteroid regimen)
- **BIOLOGICAL:** AGTC-501 (low dose and standard corticosteroid regimen)
- **BIOLOGICAL:** AGTC-501 (high dose and modified corticosteroid regimen)

## Key facts

- **NCT ID:** NCT06275620
- **Lead sponsor:** Beacon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-11-14
- **Primary completion:** 2025-11
- **Final completion:** 2029-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06275620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06275620, "A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06275620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*